{
 "name": "智擎",
 "slug": "tw-4162",
 "aliases": [
  "智擎生技製藥股份有限公司",
  "PEI",
  "4162"
 ],
 "ticker": "4162",
 "industry": "生技醫療業",
 "website": "https://www.pharmaengine.com",
 "summary": "智擎（4162）是上櫃的生技醫療類股公司，2002 年成立，2012 年上櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "智擎生技製藥股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "英文簡稱",
   "value": "PEI",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心上櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "上櫃日期",
   "value": "2012-09-18",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "成立日期",
   "value": "2002-08-12",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "董事長",
   "value": "許璋瑤",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "總經理",
   "value": "王宏仁",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "實收資本額",
   "value": 1436776400,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "公司網址",
   "value": "https://www.pharmaengine.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "月營收（2026-09）",
   "value": 223437,
   "unit": "新台幣千元",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔二手來源不在白名單；本次回查官方115年09月營收申報，原claim/value/unit/as_of均一致並保留。出表日1151017；僅更正source及補此note。"
  },
  {
   "claim": "月營收年增率（2026-09）",
   "value": 13.07,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔二手來源不在白名單；本次回查官方115年09月營收申報，原claim/value/unit/as_of均一致並保留。出表日1151017；僅更正source及補此note。"
  },
  {
   "claim": "累計營收年增率（2026 年 1 月至 09 月）",
   "value": 22.18,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔二手來源不在白名單；本次回查官方115年09月營收申報，原claim/value/unit/as_of均一致並保留。出表日1151017；僅更正source及補此note。"
  },
  {
   "claim": "管線：PEP02（ONIVYDE／nanoliposomal irinotecan）",
   "value": "轉移性胰臟癌第一線及第二線治療｜已核准上市｜台灣；歐洲、亞洲具權利金及里程碑權益",
   "unit": "",
   "as_of": "2026-08-06",
   "source": "https://www.pharmaengine.com/en/uploads/en/Investors_2/20260806748.pdf",
   "note": "地域依簡報第9頁產品商業權利欄；不把全球藥證與智擎當地銷售權混為一談。"
  },
  {
   "claim": "管線：PEP07（CHK1抑制劑）",
   "value": "急性骨髓性白血病、被套細胞淋巴瘤｜I 期（收案中）｜澳洲、台灣",
   "unit": "",
   "as_of": "2025-07-31",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT05659732",
   "note": "NCT 編號：NCT05659732；as_of 為登錄最後更新公開日。"
  },
  {
   "claim": "管線：PEP07（CHK1抑制劑）",
   "value": "晚期或轉移性實體腫瘤｜I 期（收案中）｜台灣",
   "unit": "",
   "as_of": "2024-11-07",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT05983523",
   "note": "NCT 編號：NCT05983523；as_of 為登錄最後更新公開日。"
  },
  {
   "claim": "管線：PEP08（PRMT5:MTA抑制劑）",
   "value": "MTAP缺失之晚期或轉移性實體腫瘤｜I期劑量遞增試驗進行中｜澳洲、台灣、南韓",
   "unit": "",
   "as_of": "2026-08-06",
   "source": "https://www.pharmaengine.com/en/uploads/en/Investors_2/20260806748.pdf",
   "note": "NCT 編號：NCT06973863；南韓試驗地區採較後公司簡報，早於此之CTgov登錄尚僅列澳洲/台灣。"
  },
  {
   "claim": "授權合作：LIPORAXEL",
   "value": "Shanghai RMX Biopharma Co., Ltd.（Haihe子公司）｜台灣｜2024-11-04",
   "unit": "",
   "as_of": "2024-11-04",
   "source": "https://www.pharmaengine.com/en/investors/investors_5/87",
   "note": "獨家經銷合作；智擎負責台灣藥證申請、銷售及行銷，非產品全球授權。"
  },
  {
   "claim": "催化劑：PEP07",
   "value": "組合治療試驗首位病患收案｜2026年底前（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-08-06",
   "source": "https://www.pharmaengine.com/en/uploads/en/Investors_2/20260806748.pdf",
   "note": "此為公司預估時程，未視為已開始組合治療。"
  },
  {
   "claim": "催化劑：PEP08",
   "value": "I期劑量遞增試驗完成病患收案｜2026年底（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-08-06",
   "source": "https://www.pharmaengine.com/en/uploads/en/Investors_2/20260806748.pdf"
  },
  {
   "claim": "催化劑：PEP07",
   "value": "試驗登錄預估主要完成日｜2026-12-31（登錄預估）｜已公告",
   "unit": "",
   "as_of": "2025-07-31",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT05659732",
   "note": "NCT 編號：NCT05659732；登錄之 ESTIMATED 日期，不是結果公布日或已完成證據；as_of 為 lastUpdatePostDate。"
  },
  {
   "claim": "催化劑：PEP07",
   "value": "試驗登錄預估主要完成日｜2027-02-25（登錄預估）｜已公告",
   "unit": "",
   "as_of": "2024-11-07",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT05983523",
   "note": "NCT 編號：NCT05983523；登錄之 ESTIMATED 日期，不是結果公布日或已完成證據；as_of 為 lastUpdatePostDate。"
  },
  {
   "claim": "催化劑：PEP08",
   "value": "試驗登錄預估主要完成日｜2027-12（登錄預估）｜已公告",
   "unit": "",
   "as_of": "2026-02-13",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06973863",
   "note": "NCT 編號：NCT06973863；登錄之 ESTIMATED 日期，不是結果公布日或已完成證據；as_of 為 lastUpdatePostDate。"
  },
  {
   "claim": "管線：PEP02（ONIVYDE／nanoliposomal irinotecan）",
   "value": "胰臟癌第一線組合療法｜新適應症上市後變更申請已受理｜日本",
   "unit": "",
   "as_of": "2026-01-16",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01",
   "note": "查詢4162、115年度、全年度、序號4。發言日期2026-01-16 15:00:35；主旨：智擎公司公告將獲得再授權收入美金150萬元。正文載明日本主管機關接受Servier提出1L PDAC dossier；為來源當日之申請受理狀態，不等於核准上市，亦非已收款。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-4162.json",
 "generated_at": "2026-10-23T01:06:05.573Z"
}